Health Canada approves injectable hydromorphone to treat opioid addiction

16 May 2019 - Canada is first country to approve the pain drug for severe opioid use disorder, says Health ...

Read more →

Helping Canadians get faster access to the prescription drugs they need to live healthier lives

13 May 2019 - Government of Canada consults on new approach to fast-track the review of treatments for serious, rare ...

Read more →

First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer

8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...

Read more →

Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada

3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...

Read more →

Cresemba now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis

2 May 2019 - AVIR Pharma is pleased to announce that Cresemba (isavuconazole, as isavuconazonium sulphate), an anti-fungal approved for the ...

Read more →

New drug submission filed for Vascepa with Health Canada

29 April 2019 - Amarin Corporation today announced that its licensee in Canada, HLS Therapeutics has filed a new drug ...

Read more →

Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis

18 April 2019 - Approval of Skyrizi (risankizumab) is based on results from clinical studies showing significant improvement in levels of ...

Read more →

Increasing access to new treatments for special patient populations

16 April 2019 - Health Canada is helping Canadians get timely access to new drugs. ...

Read more →

Recordati to seek Canadian approval for kidney disease drug

17 April 2019 - Italy’s Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which ...

Read more →

Health Canada issues Notice of Compliance with Conditions for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinom

11 April 2019 - Cutaneous squamous cell carcinoma is the second most common skin cancer in Canada. ...

Read more →

Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis

10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance  for Truxima (rituximab), the ...

Read more →

Health Canada approves new drug to treat metastatic breast cancer through international and domestic joint reviews

9 April 2019 - Canadians want improved access to the most recent and innovative treatment options for themselves and their ...

Read more →

Supporting greater availability of lower cost generic drugs for Canadians

4 April 2019 - Canadians want improved access to a wider range of safe and affordable medications.  ...

Read more →

Health Canada approves Cimzia (certolizumab pegol) for moderate-to-severe psoriasis

25 March 2019 - Health Canada also approves label updates in pregnancy and breast-feeding ...

Read more →

New treatment option now available in Canada for newly diagnosed patients with advanced lung cancer

18 March 2019 - Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy reduced the risk of death by half compared ...

Read more →